RCS - Graft Polymer (UK) - Proactive Investors Interview with CEO and Chair

Solvonis Therapeutics

18/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241218:nRSR5071Qa&default-theme=true

RNS Number : 5071Q  Graft Polymer (UK) PLC  18 December 2024

RNS Reach - non-regulatory announcement

18 December 2024

Graft Polymer (UK) Plc

("Graft Polymer" or the "Company")

 

Proactive Investors interviews with CEO and Chairman

 

Graft Polymer, an innovative biotechnology company co-developing therapeutics
for mental health disorders, announces interviews on Proactive Investors with
Anthony Tennyson, CEO and Dennis Purcell, Chairman. The interview with Anthony
Tennyson can we viewed now at
https://www.proactiveinvestors.co.uk/LON:GPL/Graft-Polymer-UK-PLC
(https://www.proactiveinvestors.co.uk/LON:GPL/Graft-Polymer-UK-PLC) and the
interview with Dennis Purcell will be available from this Thursday, 19
December 2024.

 

 

Enquiries:

 

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director.
anthonytennyson@graftpolymer.co.uk

 

Allenby Capital (Financial Adviser and Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

 

 

About Graft Polymer (UK) Plc

 

Graft Polymer (UK) Plc is an innovative biotechnology company focused on
developing intellectual property relating to the treatment of mental health
and substance use disorders, and the co-development of therapeutics for mental
health disorders.  Our mission is to improve outcomes for individuals
suffering from these conditions, with an initial focus on trauma-related
mental health disorders, such as PTSD, which affected approximately 13 million
adults in the U.S. in 2020, with the Company estimating a current affected
population of 20 million across the US, UK and key EU markets.

 

For more information, please visit www.graftpolymer.co.uk
(http://www.graftpolymer.co.uk) .

 

About Reach announcements

This is an RNS Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGGBDDSDBDGSI